iShares MSCI EAFE Min Vol Factor ETF
iShares · Tracks MSCI EAFE Minimum Volatility (USD) Index · Inception Oct 18, 2011
Composite score
Based on a 0.20% expense ratio.
Based on $5.08B in net assets.
Top-10 holdings represent 15.1% of net assets.
Low Volatility Factor base · ETF wrapper · 3.17% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use EFAV in our tools
Tool · Cost
Compare EFAV's fee against another fund
Compounds the 0.20% expense ratio against a peer over decades.
Tool · Overlap
Compare EFAV's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar Low Volatility Factor funds.
Tool · TLH
Find a tax-loss harvesting partner for EFAV
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | ENI S.P.A. | 1.68% |
| 2 | TOTALENERGIES SE | 1.67% |
| 3 | EQUINOR ASA | 1.59% |
| 4 | SHELL PLC | 1.57% |
| 5 | Iberdrola, S.A. | 1.51% |
| 6 | DBS GROUP HOLDINGS LTD | 1.47% |
| 7 | ORANGE SA | 1.43% |
| 8 | Swisscom AG | 1.41% |
| 9 | Takeda Pharmaceutical Company Limited | 1.40% |
| 10 | Novartis AG | 1.36% |
Compare EFAV with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open EFAV at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.